Key facts
- ThunderBio’s last known valuation is $61.9M (Sep 2022).
- It has raised $19.8M; the latest was Later Stage VC in Oct 2025.
- Notable investors include Detong Capital, Guangzhou Jinkong Fund, BridgeOne Capital China, Guangzhou Ambition (LBP) Pharmaceutical Technology, HKUST Business School — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for ThunderBio
- ·The full record, as it builds
Funding rounds
No funding rounds for ThunderBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ThunderBio
Developer of digital PCR diagnostic system designed to focus on the microfluidic technology in vitro diagnostic platforms. The PCR system can digitize the medical test results, and the results can be used for medication guidance or predictive treatment, etc, providing reliable digital support for medical practitioners and researchers.
- Sector
- Healthcare
- HQ
- Jiaxing, China
- Employees
- 14
- Website
- thunder-bio.com/
- Ownership
- Privately Held (backing)
ThunderBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ThunderBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ThunderBio in its N-PORT filings yet. We sweep new filings monthly.